Diabetes is becoming a major public health threat in China[@b1]. Despite improvements in the management of diabetes, diabetic peripheral neuropathy (DPN) has become the most commonly reported chronic diabetic complication, affecting up to half of diabetic patients[@b2]. DPN causes serious compilations, such as foot ulcers and gangrene, leading to lower limb amputation, all of which reduce the quality of life in diabetic patients[@b3][@b4]. Several pathogenic mechanisms have been reported to be involved in DPN, including microangiopathy, oxidative stress, inflammation, the polyol pathway, glycation, and ligand activation[@b5][@b6][@b7][@b8]. However, the underlying pathophysiology of DPN is complex and has not been fully elucidated.

Magnesium is the fourth most abundant cation in the human body. It acts as a co-factor for numerous enzymatic reactions and exerts important roles in many biological processes[@b9][@b10]. Recent studies have demonstrated that low serum magnesium is independently associated with an increased risk of type 2 diabetes (T2DM)[@b11][@b12][@b13], cardiovascular disease[@b14], and foot ulcers[@b15]. Furthermore, there is increasing evidence that hypomagnesemia is associated with microvascular complications of T2DM, such as nephropathy[@b16][@b17][@b18] and retinopathy[@b19][@b20]. The relationship between serum magnesium and DPN remains unclear and controversial, with conflicting results observed regarding the effects of serum magnesium levels on nerve conduction (NC) and the presence of neuropathic pain[@b21][@b22][@b23]. Therefore, we designed this cross-sectional study to examine the association between serum magnesium levels and peripheral nerve function in patients with T2DM.

Results
=======

Patient characteristics
-----------------------

The demographic and clinical characteristics of patients with normal and abnormal NC are illustrated in [Table 1](#t1){ref-type="table"}. Among the 978 patients, 746 (76.28%) had normal NC and 232 (23.72%) had abnormal NC. Abnormal NC was significantly associated with older age, longer diabetes duration (all *P* \< 0.001). Besides, HbA1c, systolic blood pressure (SBP), urinary albumin excretion (UAE) and the percentage of anti-hypertensive therapy were significantly higher in the abnormal NC group (all *P* \< 0.05). Interestingly, serum magnesium levels were significantly lower in the abnormal NC group (*P* = 0.048).

Association of serum magnesium levels with NC parameters
--------------------------------------------------------

Patients were further divided into tertiles according to serum magnesium levels (low tertile: ≤0.85 mmol/L; medium tertile: 0.85 to 0.92 mmol/L, and high tertile: \>0.92 mmol/L). As presented in [Table 2](#t2){ref-type="table"}, patients in the high tertile of serum magnesium were older, had lower levels of body mass index (BMI), HbA1c, estimated glomerular filtration rate (eGFR) and UAE than those in the low and medium tertile (all *P* \< 0.001). Besides, diastolic blood pressure (DBP), high-density lipoprotein cholesterol (HDL-c), triglycerides (TG), creatinine, and the percentage of anti-hypertensive therapy were significantly different among the 3 tertiles (all *P* \< 0.05).

All individual nerve conduction studies (NCS) parameters were analyzed firstly. Significant differences were observed in amplitude for motor tibial (*P* = 0.046), sensory ulnar (*P* = 0.044) and sensory sural nerves (*P* = 0.012) among the three tertiles of serum magnesium ([Table 2](#t2){ref-type="table"}). However, there was no significant difference in the conduction velocity (CV) and latency for all tested nerves. In addition, there was no significant difference of CV, amplitude and latency for peroneal nerve among serum magnesium tertiles ([Supplementary Table S1](#S1){ref-type="supplementary-material"}).

Next, composite z scores of CV, latency, and amplitude were calculated, respectively. The results showed that the composite z score of amplitude significantly increased with increasing tertiles of magnesium (−0.60 ± 0.02 vs. −0.57 ± 0.02 vs. −0.48 ± 0.03, *P* for trend = 0.001; [Fig. 1b](#f1){ref-type="fig"}). In addition, post-hoc analysis using Bonferroni correction showed significant differences in the composite z score of amplitude between the medium and high tertile (*P* = 0.047) as well as between the low and high tertile (*P* = 0.002). Notably, the result regarding the composite z score of amplitude was consistent with that of amplitude analysis in individual nerves. However, no significant trends were observed among tertiles of magnesium with respect to the composite z scores of both CV (*P* for trend = 0.337) and latency (*P* for trend = 0.331).

Multiple linear regression analysis showed that serum magnesium was still positively correlated with the composite z score of amplitude (*β* = 0.102, *P* = 0.007; [Table 3](#t3){ref-type="table"}), after adjusting for age, sex, diabetes duration, HbA1c level, anti-hypertensive therapy, SBP, DBP, UAE (model 1). Given that serum magnesium has been shown to be negatively correlated with eGFR[@b14][@b24] and our results were also in accordance with this observation (r = −0.19, P\<0.001), eGFR was additionally included for adjustment (model 2). We found that the association of serum magnesium with the composite z score of amplitude (*β* = 0.095, *P* = 0.014) remained significant.

Discussion
==========

Serum magnesium has a close relationship with T2DM[@b11][@b12]. It has been shown that lower serum magnesium levels are significantly associated with increased risk of T2DM[@b13] and with various complications of diabetes, including cardiovascular disease[@b14], nephropathy[@b16][@b17][@b18][@b25], retinopathy[@b19][@b20], and foot ulcers[@b15]. However, data regarding the relationship between serum magnesium and DPN are limited and controversial. Previous research has shown that magnesium supplementation could improve both NC in type 1 diabetic patients[@b21] and symptoms of neuropathy in streptozocin-induced diabetic (STZ-D) rats[@b22]. In contrast, Hyassat *et al*. found no association between hypomagnesemia and neuropathy when the diagnosis of neuropathy was based on neuropathic symptoms or the presence of an abnormality of NC[@b23].

In this study, we performed NCS in all patients, which is an accurate, sensitive, and reproducible method for evaluating DPN[@b26][@b27]. Additionally, composite z scores of NCS parameters were constructed for six nerves, including motor nerves (median, ulnar, and tibial) and sensory nerves (median, ulnar, and sural)[@b28]. We found that serum magnesium levels were independently associated with the amplitude, but not with CV and latency. Interestingly, it is well established that low amplitude is an indicator of axonal degeneration, whereas decreased CV and prolonged latency are useful markers for demyelination[@b29]. It is plausible to postulate that serum magnesium levels might affect peripheral nerve function through axonal degeneration.

Magnesium exerts wide-range effects on many biological processes. First of all, increasing evidences indicated that magnesium can not only decrease tissue susceptibility to oxidative damage, but also has indirect antioxidant capacity[@b30][@b31][@b32]. Parvizi *et al*. found that treatment of STZ-D rats with MgSO4 can attenuate oxidative stress in the renal tissue as indicated by decreased levels of malondialdehyde[@b33]. Additionally, several studies have demonstrated that low serum magnesium concentration is closely associated with increased inflammation[@b34][@b35]. Furthermore, it has been reported that magnesium can increase intracellular inositol concentrations by enhancing the affinity of transport system for inositol, thus inhibiting further damage of the nervous system[@b32][@b36]. Although the multifactorial pathogenesis of DPN is still poorly understood, oxidative stress, inflammation and decreased intracellular inositol concentrations contribute to the progression of DPN[@b5][@b8][@b32][@b37]. In addition, myo-inositol may be at least partially responsible for the axonal degeneration[@b38]. Further studies are warranted to reveal the direct effects of low serum magnesium levels on axonal degeneration. Notably, in non-diabetic subjects, we did not observe any association between serum magnesium levels and the composite z scores of all NCS parameters, suggesting that magnesium will only affect NC function in diabetic patients.

In summary, our data showed that lower serum magnesium levels were significantly associated with lower composite z score of amplitude in patients with T2DM, indicating low serum magnesium levels might affect peripheral nerve function through axonal degeneration. Our finding suggested that low serum magnesium levels may underlie many of the pathophysiologic features of DPN. Further studies will provide a novel prospective strategy for DPN.

Methods
=======

Study population
----------------

A total of 978 T2DM patients were recruited from the Shanghai Diabetes Institute Inpatient Database of Shanghai Jiao Tong University Affiliated Sixth People's Hospital between April 2013 and August 2014. Inclusion criteria include the following: (1) established T2DM diagnosed according to the 1999 WHO definition (fasting plasma glucose ≥7.0 mmol/L and/or 2-h plasma glucose ≥11.1 mmol/L); (2) valid data of NCS. Exclusion criteria included: (1) missing data on age, sex, diabetes duration, and serum magnesium; (2) histories of persistent diarrhea or vomiting, progressive malignancy and severe renal insufficiency as defined by an eGFR \<60 ml·min^−1^·1.73 m^−2^; (3) current use of high-dose (\>40 mg/day) diuretics and/or magnesium supplementation; (4) histories of diseases that could affect NC (i.e., Guillain--Barre syndrome, chronic inflammatory demyelinating polyneuropathy, or carpal tunnel syndrome, etc.).

This study was conducted in accordance with the Declaration of Helsinki II and was approved by the institutional review board of Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Written informed consent was obtained from each participants.

Clinical and laboratory analysis
--------------------------------

Weight and height were measured with a standardized method by the same physician. BMI was calculated as the body weight (kg) divided by the square of the height (m). Information of alcohol use and smoking status were obtained using a standardized questionnaire. Participants consuming alcohol on a regular basis (≥30 g per week) for more than 1 year were defined as alcohol consumers[@b1]. Subjects who smoked at least one cigarette per day for over 6 months were defined as current smokers[@b39]. SBP and DBP were calculated as the average value of three measurements taken at 3 min intervals using a mercury sphygmomanometer. Information regarding anti-hypertensive therapy (i.e., Angiotensin-converting enzyme inhibitor, Angiotensin II receptor blocker, Calcium channel blocker, and β-blocker etc.) were obtained from all participants' medical records.

Blood samples were collected after an overnight fast of 8--10 h. Glycated hemoglobin (HbA1c) was determined by high-performance liquid chromatography (HLC-723 G7, Tosoh, Japan). Serum magnesium levels were measured by the xylidyl blue method (Hitachi 7600 analyzer). Serum creatinine, total cholesterol (TC), HDL-c, low-density lipoprotein cholesterol (LDL-c), and TG were determined enzymatically (Hitachi 7600 chemical analyzer). The eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula developed for the Chinese population: eGFR (ml·min^−1^ ·1.73 m^−2^) = 186 × (serum creatinine in μmol/L × 0.011)^−1.154^ × (age in years)^--0.203^ × (0.742 if female) × (1.233 if Chinese)[@b40]. UAE was obtained from at least two 24-h urine samples and determined as the mean of 24-h urine collections during the period of hospitalization.

Nerve conduction studies
------------------------

Peripheral nerve function was evaluated by NCS with the use of the EMG Myto, EBNeuro (ESAOTE, Florence, Italy), which has been described previously[@b41]. Briefly, NCS were performed by experienced electrophysiologists who were unaware of the laboratory results. During testing, temperatures were maintained at ≥35 °C for upper extremities and ≥32 °C for lower extremities. Motor nerve studies measured CV, compound muscle action potential (CMAP) amplitude, and distal latency in the median, ulnar, and tibial nerves. Sensory nerve studies contained the CV, sensory nerve action potential (SNAP) amplitude, and onset latency in the median, ulnar, and sural nerves. We then compared all obtained data with reference values from our laboratory. Throughout the study, all data were reviewed by the reading site to ensure overall quality. Abnormal NC was defined by abnormality of one or more parameters in two or more tested anatomical nerves[@b42]. Composite z scores of CV, amplitude, and latency were constructed as previously described[@b41][@b43].

F-wave analysis
---------------

Supramaximal percutaneous stimuli at the degree of 1 Hz were given to peroneal, tibial, median and ulnar nerves for ten times, respectively. F-wave was recorded at the extensor digitorum brevis, abductor hallucis muscle, abductor pollicis brevis, and abductor digiti minimi by means of the EMG Myto, EBNeuro (ESAOTE, Florence, Italy). Variables analyzed included F-wave minimum latency and persistence. F-wave persistence was defined as the number of the F-responses obtained with ten stimuli. The details of F-wave analysis were shown in [Supplementary Table S2](#S1){ref-type="supplementary-material"} and [S3](#S1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

Data were expressed as mean ± standard deviation (SD) for normal distribution variables or as median (25--75th percentiles) for skewed distribution variables. Categorical variables were presented as numbers (percentage). Differences between the normal NC group and abnormal NC group were evaluated using the Student's t-test or Mann--Whitney U test for continuous variables and the chi-squared test for categorical variables. Differences among tertiles of serum magnesium were analysed by one-way ANOVA or the Kruskal-Wallis test, as well as the chi-squared test for categorical values. Bonferroni correction was used for the post-hoc analyses. Data with a skewed distribution (including serum magnesium, and eGFR) were logarithmically transformed before analysis. Multivariate linear regression analysis was used to assess the independent associations of serum magnesium with NCS parameters after adjusting for covariates. All *P* values were two-sided, and values of *P* \< 0.05 were considered statistically significant. Statistical analyses were performed using SPSS version 19 (SPSS, Inc., Chicago, IL, USA).
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###### Characteristics of patients in the study.

  Variable                                Total (N = 978)         Normal NC (N = 746)      Abnormal NC (N = 232)    *P* value
  ---------------------------------- ------------------------- ------------------------- ------------------------- -----------
  Age (years)                              57.32 ± 12.77             56.43 ± 12.97             60.18 ± 11.65         \<0.001
  Male sex (n, %)                          541 (55.32%)              410 (54.96%)              131 (56.47%)           0.687
  Alcohol consumers (n, %)                 177 (18.17%)              128 (17.23%)               49 (21.21%)           0.170
  Current smokers (n, %)                   229 (23.44%)              171 (22.95%)               58 (25.00%)           0.520
  SBP (mmHg)                              130.64 ± 15.27            129.79 ± 14.97            133.40 ± 15.96          0.002
  DBP (mmHg)                               79.17 ± 9.03              79.20 ± 9.06              79.07 ± 8.95           0.844
  BMI (kg/m^2^)                        25.21 (22.85, 27.73)      25.11 (22.84, 27.51)      25.39 (23.15, 28.65)       0.098
  Diabetes duration (years)             8.00 (4.00, 14.00)        8.00 (3.00, 13.00)        10.00 (5.00, 15.75)      \<0.001
  HbA1c (%)                              8.00 (7.10, 9.50)         7.80 (6.90, 9.30)        8.75 (7.60, 10.10)       \<0.001
  Total cholesterol (mmol/L)             4.59 (4.01, 5.32)         4.62 (4.04, 5.31)         4.50 (3.91, 5.36)        0.555
  HDL-c (mmol/L)                         1.02 (0.87, 1.23)         1.02 (0.87, 1.23)         1.02 (0.87, 1.21)        0.793
  LDL-c(mmol/L)                          2.80 (2.21, 3.38)         2.82 (2.26, 3.38)         2.74 (2.14, 3.39)        0.361
  Triglyceride (mmol/L)                  1.39 (1.01, 1.99)         1.38 (1.02, 1.97)         1.42 (1.01, 2.03)        0.863
  Serum creatinine (μmol/L)            67.00 (55.00, 78.00)      67.00 (55.00, 78.00)      68.00 (56.50, 78.00)       0.505
  eGFR (ml · min^−1^ · 1.73 m^−2^)    129.56 (111.69, 149.36)   130.01 (112.95, 149.75)   128.18 (106.21, 148.77)     0.284
  UAE (mg/24h)                          9.82 (6.27, 24.60)        9.32 (6.14, 20.47)        14.10 (7.08, 43.12)      \<0.001
  Anti-hypertensive therapy (n, %)         532 (54.40%)              385 (51.61%)              147 (63.36%)           0.002
  Serum magnesium (mmol/L)               0.88 (0.83, 0.93)         0.88 (0.83, 0.93)         0.87 (0.82, 0.92)        0.048

Data were expressed as mean ± standard deviation (SD) for normal distribution variables or as median (25--75th percentiles) for skewed distribution variables. Categorical variables were expressed as numbers (percentage).

NC, nerve conduction; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HbA1c, glycated hemoglobin; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; and UAE, urinary albumin excretion.

###### Characteristics of patients and nerve conduction parameters, according to tertiles of serum magnesium.

  Variable                                Serum magnesium              *P* value                                   
  ---------------------------------- ------------------------- ------------------------- ------------------------- ---------
  Serum magnesium (mmol/L)                     ≤0.85                  0.85--0.92                  \>0.92                
  Age (years)                              54.98 ± 13.27             58.40 ± 12.69             59.13 ± 11.68        \<0.001
  Male sex (n, %)                          190 (51.91%)              194 (57.06%)              157 (57.72%)          0.250
  Alcohol consumers (n, %)                  64 (17.53%)               65 (19.23%)               48 (17.71%)          0.822
  Current smokers (n, %)                    78 (21.31%)               90 (26.55%)               61 (22.43%)          0.234
  SBP (mmHg)                              130.89 ± 14.81            131.28 ± 15.36            129.50 ± 15.77         0.333
  DBP (mmHg)                               79.36 ± 8.47              80.20 ± 9.55              77.63 ± 8.94          0.002
  BMI (kg/m^2^)                        25.64 (23.24, 28.48)      25.20 (22.91, 27.66)      24.22 (22.41, 26.68)     \<0.001
  Diabetes duration (years)             9.00 (4.00, 14.00)        8.00 (4.00, 13.00)        8.00 (3.00, 14.00)       0.344
  HbA1c (%)                             8.60 (7.30, 10.00)         8.20 (7.20, 9.50)         7.40 (6.70, 8.70)      \<0.001
  Total cholesterol (mmol/L)             4.55 (4.00, 5.32)         4.65 (4.06, 5.41)         4.60 (3.99, 5.26)       0.495
  HDL-c (mmol/L)                         0.99 (0.86, 1.17)         1.02 (0.88, 1.23)         1.07 (0.89, 1.29)       0.006
  LDL-c (mmol/L)                         2.79 (2.14, 3.35)         2.87 (2.32, 3.41)         2.71 (2.17, 3.32)       0.221
  Triglyceride (mmol/L)                  1.50 (1.09, 2.21)         1.37 (1.00, 1.99)         1.29 (0.97, 1.82)       0.002
  Serum creatinine (μmol/L)            64.00 (52.00, 77.00)      66.00 (56.00, 76.00)      70.00 (59.00, 81.00)     \<0.001
  eGFR (ml · min^−1^ · 1.73 m^−2^)    134.23 (114.51, 158.77)   131.49 (113.33, 148.26)   122.92 (104.84, 139.82)   \<0.001
  UAE (mg/ 24h)                         13.06 (7.00, 34.40)       9.50 (6.29, 24.86)        7.50 (5.63, 14.95)      \<0.001
  Anti-hypertensive therapy (n, %)         218 (59.56%)              187 (55.00%)              127 (46.69%)          0.005
  Motor median CV (m/s)                53.85 (51.20, 56.81)      53.75 (51.20, 56.63)      54.45 (51.33, 58.10)      0.105
  Motor median amplitude (mv)            5.95 (4.28, 7.63)         5.80 (4.10, 7.50)         6.40 (4.50, 8.20)       0.130
  Motor median latency (ms)              3.45 (3.10, 3.90)         3.50 (3.10, 3.80)         3.40 (3.00, 3.80)       0.201
  Motor ulnar CV (m/s)                 58.70 (54.30, 62.90)      58.30 (54.51, 62.18)      59.00 (54.79, 63.20)      0.412
  Motor ulnar amplitude (mv)             4.40 (3.58, 5.70)         4.50 (3.50, 5.48)         4.75 (3.60, 6.00)       0.164
  Motor ulnar latency (ms)               2.45 (2.20, 2.70)         2.40 (2.20, 2.70)         2.40 (2.20, 2.60)       0.125
  Motor tibial CV (m/s)                42.90 (40.28, 47.10)      43.31 (40.70, 47.90)      43.78 (41.50, 47.10)      0.064
  Motor tibial amplitude (mv)            6.10 (3.90, 8.13)         6.40 (4.13, 8.88)         6.60 (4.63, 9.38)       0.046
  Motor tibial latency (ms)              3.60 (3.20, 4.10)         3.50 (3.20, 4.00)         3.50 (3.10, 4.10)       0.517
  Sensory median CV (m/s)              56.00 (50.78, 61.93)      56.00 (50.08, 61.13)      55.20 (51.63, 60.90)      0.836
  Sensory median amplitude (mv)         9.30 (6.10, 13.00)        9.00 (5.75, 13.93)        10.00 (6.40, 15.00)      0.124
  Sensory median latency (ms)            2.50 (2.30, 2.80)         2.50 (2.20, 2.80)         2.50 (2.30, 2.70)       0.791
  Sensory ulnar CV (m/s)               58.00 (52.40, 62.50)      57.11 (52.30, 61.90)      58.00 (52.20, 62.50)      0.926
  Sensory ulnar amplitude (mv)          7.95 (5.20, 10.50)        8.30 (5.90, 11.60)        8.35 (5.80, 11.00)       0.044
  Sensory ulnar latency (ms)             2.10 (1.90, 2.30)         2.10 (1.92, 2.40)         2.10 (1.90, 2.38)       0.792
  Sensory sural CV (m/s)               46.20 (42.38, 51.55)      46.95 (42.90, 52.08)      46.85 (42.90, 50.70)      0.745
  Sensory sural amplitude (mv)          10.00 (5.88, 15.00)       10.20 (6.60, 16.00)       11.00 (7.03, 18.80)      0.012
  Sensory sural latency (ms)             1.90 (1.50, 2.40)         2.00 (1.60, 2.50)         1.90 (1.50, 2.40)       0.183

Data were expressed as mean ± standard deviation (SD) for normal distribution variables or as median (25--75th percentiles) for skewed distribution variables. Categorical variables were expressed as numbers (percentage).

SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HbA1c, glycated hemoglobin; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion; and CV, conduction velocity.

###### Association of serum magnesium levels with nerve conduction parameters after adjustments.

  Variable                           Serum magnesium  
  --------------------------------- ----------------- -------
  Model 1                                             
   Composite z score of CV                0.010        0.792
   Composite z score of amplitude         0.102        0.007
   Composite z score of latency          −0.025        0.483
  Model 2                                             
   Composite z score of CV                0.004        0.918
   Composite z score of amplitude         0.095        0.014
   Composite z score of latency          −0.023        0.526

CV, conduction velocity.

Model 1: adjusted for age, sex, diabetes duration, HbA1c, anti-hypertensive therapy, systolic blood pressure, diastolic blood pressure, urinary albumin excretion.

Model 2: Model 1 + estimated glomerular filtration rate.
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